Welcome to Lycera Corp

At Lycera, we are pioneering an innovative approach to developing novel oral medicines to treat high unmet-need autoimmune diseases. Lycera is targeting two novel autoimmune pathways to develop a new class of small molecules to treat immune disorders such as rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease. Lycera’s world-class team and biological insights in the immunology and inflammation arenas uniquely position the company to realize the promise of translating cutting-edge science into first-in-class oral therapies.

QUICKLINKS